{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:11:05Z","timestamp":1782817865256,"version":"3.54.5"},"reference-count":44,"publisher":"FapUNIFESP (SciELO)","issue":"suppl 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  BACKGROUND:  Gastroesophageal reflux disease (GERD) is a clinical condition that develops when the reflux of stomach contents causes troublesome symptoms and\/or complications. Transient lower esophageal sphincter relaxation is the main pathophysiological mechanism of GERD. Symptoms and complications can be related to the reflux of gastric contents into the esophagus, oral cavity, larynx and\/or the lung. Symptoms and other possible manifestations of GERD are heartburn, regurgitation, dysphagia, non-cardiac chest pain, chronic cough, chronic laryngitis, asthma and dental erosions. The proton pump inhibitor (PPI) is the first-choice drug and the most commonly medication used for the treatment of GERD. The most widespread definition of Refractory GERD is the clinical condition that presents symptoms with partial or absent response to twice-daily PPI therapy. Persistence of symptoms occurs in 25% to 42% of patients who use PPI once-daily and in 10% to 20% who use PPI twice-daily.  OBJECTIVE:  The objective is to describe a review of the current literature, highlighting the causes, diagnostic aspects and therapeutic approach of the cases with suspected reflux symptoms and unresponsive to PPI.  CONCLUSION:  Initially, the management of PPI refractoriness consists in correcting low adherence to PPI therapy, adjusting the PPI dosage and emphasizing the recommendations on lifestyle modification change, avoiding food and activities that trigger symptoms. PPI decreases the number of episodes of acid reflux; however, the number of \u201cnon-acid\u201d reflux increases and the patient continues to have reflux despite PPI. In this way, it is possible to greatly reduce greatly the occurrence of symptoms, especially those dependent on the acidity of the refluxed material. Response to PPI therapy can be evaluated through clinical, endoscopic, and reflux monitoring parameters. In the persistence of the symptoms and\/or complications, other causes of Refractory GERD should be suspected. Then, diagnostic investigation must be initiated, which is supported by clinical parameters and complementary exams such as upper digestive endoscopy, esophageal manometry and ambulatory reflux monitoring (esophageal pH monitoring or esophageal impedance-pH monitoring). Causes of refractoriness to PPI therapy may be due to the true Refractory GERD, or even to other non-reflux diseases, which can generate symptoms similar to GERD. There are several causes contributing to PPI refractoriness, such as inappropriate use of the drug (lack of patient adherence to PPI therapy, inadequate dosage of PPI), residual acid reflux due to inadequate acid suppression, nocturnal acid escape, \u201cnon-acid\u201d reflux, rapid metabolism of PPI, slow gastric emptying, and misdiagnosis of GERD. This is a common cause of failure of the clinical treatment and, in this case, the problem is not the treatment but the diagnosis. Causes of misdiagnosis of GERD are functional heartburn, achalasia, megaesophagus, eosinophilic esophagitis, other types of esophagitis, and other causes. The diagnosis and treatment are specific to each of these causes of refractoriness to clinical therapy with PPI.<\/jats:p>","DOI":"10.1590\/s0004-2803.201800000-48","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T16:06:45Z","timestamp":1538582805000},"page":"85-91","source":"Crossref","is-referenced-by-count":21,"title":["ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?"],"prefix":"10.1590","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-2185","authenticated-orcid":false,"given":"Rimon Sobhi","family":"AZZAM","sequence":"first","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2018,10,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","article-title":"The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus","volume":"101","author":"Vakil van N","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2012.444","article-title":"Guidelines for the diagnosis and management of gastroesophageal reflux disease","volume":"108","author":"Katz PO","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/gut.2004.051821","article-title":"Epidemiology of gastro-oesophageal reflux disease: A systematic review","volume":"54","author":"Dent J","year":"2005","journal-title":"Gut"},{"key":"ref4","first-page":"29","article-title":"Relationship between upper gastrointestinal symptoms and lifestyle, psychosocial factors and comorbidity in the general population: Results from the domestic\/international gastroenterology surveillance study (DIGEST)","volume":"231","author":"Stanghellini V","year":"1999","journal-title":"Scand J Gastroenterol"},{"key":"ref5","series-title":"Desafios terap\u00eauticos na pr\u00e1tica do gastroenterologista","first-page":"1","volume-title":"Doen\u00e7a do refluxo gastroesof\u00e1gico refrat\u00e1ria","author":"Nasi A","year":"2017"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/gast.1997.v112.pm9178669","article-title":"Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis","volume":"112","author":"Chiba N","year":"1997","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000091298","article-title":"Acid suppression therapy: where do we go from here?","volume":"24","author":"Scarpignato C","year":"2006","journal-title":"Dig Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1590\/S0004-28032006000400017","article-title":"Doen\u00e7a do refluxo gastroesof\u00e1gico: revis\u00e3o ampliada","volume":"43","author":"Nasi A","year":"2006","journal-title":"Arq Gastroenterol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/j.gastro.2010.05.016","article-title":"Persistent reflux symptoms in the proton pump inhibitor era: the changing face of gastroesophageal reflux disease","volume":"139","author":"Dellon ES","year":"2010","journal-title":"Gastroenterology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.bpg.2010.10.004","article-title":"An algorithm for diagnosis and treatment of refractory GERD","volume":"24","author":"Hershcovici T","year":"2010","journal-title":"Best Pract Res ClinGastroenterol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ncpgasthep0979","article-title":"How to manage refractory GERD","volume":"4","author":"Richter J","year":"2007","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11894-008-0052-5","article-title":"Refractory GERD: what is it?","volume":"10","author":"Fass R","year":"2008","journal-title":"Curr Gastroenterol Rep"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1111\/j.1365-2036.2007.03529.x","article-title":"Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors - a follow-up study of intraluminal-impedance guided therapy","volume":"26","author":"Becker V","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"ref14","first-page":"1","article-title":"A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease","volume":"30","author":"Hillman L","year":"2017","journal-title":"Dis Esophagus"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s10620-005-3001-2","article-title":"A prospective study of gastric acid analysis and esophageal acid exposure in patients with gastroesophageal reflux refractory to medical therapy","volume":"50","author":"Ahlawat SK","year":"2005","journal-title":"Dig Dis Sci"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2982.2012.01888.x","article-title":"PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis","volume":"24","author":"Weijenborg PW","year":"2012","journal-title":"Neurolgastroenterol Motil"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2036.2011.04774.x","article-title":"Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease","volume":"34","author":"Becher A","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1442-2050.2011.01227.x","article-title":"Low levels of adherence with proton pump inhibitor therapy contribute to therapeutic failure in gastroesophageal reflux disease","volume":"25","author":"Dal-Paz K","year":"2012","journal-title":"Dis Esophagus"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0002-9343(01)00901-9","article-title":"Patterns of proton pump inhibitor use in clinical practice","volume":"111","author":"Barrison AF","year":"2001","journal-title":"Am J Med"},{"key":"ref20","first-page":"342","article-title":"An\u00e1lise da prescri\u00e7\u00e3o ambulatorial de omeprazol no Hospital das Cl\u00ednicas da USP","volume":"31","author":"Freire CCF","year":"2012","journal-title":"Gastroenterol Endosc Dig"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1046\/j.1365-2036.2003.01423.x","article-title":"Non-erosive reflux disease (NERD) - acid reflux and symptom patterns","volume":"17","author":"Martinez SD","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"ref22","first-page":"1532","article-title":"Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls","volume":"91","author":"Kuo B","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s10620-005-2960-7","article-title":"The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications","volume":"50","author":"Bautista JM","year":"2005","journal-title":"Dig Dis Sci"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1572-0241.2005.41210.x","article-title":"The role of esophageal pH monitoring in symptomatic patients on PPI therapy","volume":"100","author":"Charbel S","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1007\/s10620-007-0186-6","article-title":"Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy","volume":"53","author":"Karamanolis G","year":"2008","journal-title":"Dig Dis Sci"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/j.1572-0241.2008.02033.x","article-title":"Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: \u2018on\u2019 or \u2018off\u2019 proton pump inhibitor?","volume":"103","author":"Hemmink GJ","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1053\/gast.2001.24841","article-title":"Acid, nonacid and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings","volume":"120","author":"Sifrim D","year":"2001","journal-title":"Gastroenterology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"119S","DOI":"10.1016\/S0002-9343(03)00209-2","article-title":"Use of multichannel intraluminal impedance to document proximal esophageal and pharyngeal nonacid reflux episodes","volume":"115","author":"Tutuian R","year":"2003","journal-title":"Am J Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1365-2036.2003.01394.x","article-title":"Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH","volume":"17","author":"Vela MF","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1136\/gut.52.10.1397","article-title":"Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastrooesophageal reflux refractory to proton pump inhibitors","volume":"52","author":"Koek GH","year":"2003","journal-title":"Gut"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2217\/pgs.11.4","article-title":"Update on the pharmacogenomics of proton pump inhibitors","volume":"12","author":"Hagym\u00e1si K","year":"2011","journal-title":"Pharmacogenomics"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2036.1999.00022.x","article-title":"Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole","volume":"13","author":"Ishizaki T","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"ref33","first-page":"14","article-title":"Motilidade g\u00e1strica: fisiopatologia e m\u00e9todos de estudo","volume":"2","author":"Troncon LEA","year":"2008","journal-title":"REPM"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1053\/j.gastro.2005.08.060","article-title":"Functional esophageal disorders","volume":"130","author":"Galmiche JP","year":"2006","journal-title":"Gastroenterology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1053\/j.gastro.2016.02.012","article-title":"Functional esophageal disorders","volume":"150","author":"Aziz Q","year":"2016","journal-title":"Gastroenterology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1053\/j.gastro.2007.08.017","article-title":"Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment","volume":"133","author":"Furuta GT","year":"2007","journal-title":"Gastroenterology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1590\/S1807-59322011000400006","article-title":"Eosinophilic esophagitis in patients with typical gastroesophageal reflux disease symptoms refractory to proton pump inhibitor","volume":"66","author":"S\u00e1 CC","year":"2011","journal-title":"Clinics"},{"key":"ref38","series-title":". Edi\u00e7\u00f5es monotem\u00e1ticas FBG - doen\u00e7a do refluxo gastroesof\u00e1gico","first-page":"57","volume-title":"Esofagite eosinof\u00edlica e DRGE","author":"Azzam RS","year":"2011"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.12998\/wjcc.v4.i12.413","article-title":"Lymphocytic esophagitis: report of three cases and review of the literature","volume":"4","author":"Jideh B","year":"2016","journal-title":"World J Clin Cases"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3748\/wjg.v23.i6.949","article-title":"Lymphocytic esophagitis: still an enigma a decade later","volume":"23","author":"Rouphael C","year":"2017","journal-title":"World J Gastroenterol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1309\/7LABLGY08UEM3H26","article-title":"Lymphocytic esophagitis: a histologic subset of chronic esophagitis","volume":"125","author":"Rubio CA","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00004836-198106000-00003","article-title":"Drug-induced esophagitis","volume":"3","author":"Mason SJ","year":"1981","journal-title":"J Clin Gastroenterol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1442-2050.2009.00972.x","article-title":"Drug-induced esophagitis","volume":"22","author":"Zografos GN","year":"2009","journal-title":"Dis Esophagus"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1055\/s-2005-870129","article-title":"Pill induced esophageal injury: endoscopic features and clinical outcomes","volume":"37","author":"Abid S","year":"2005","journal-title":"Endoscopy"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v55s1\/1678-4219-ag-s0004280320180000048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T15:53:11Z","timestamp":1545407591000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032018000500085&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,4]]},"references-count":44,"journal-issue":{"issue":"suppl 1","published-online":{"date-parts":[[2018,11]]}},"alternative-id":["S0004-28032018000500085"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.201800000-48","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"value":"1678-4219","type":"electronic"},{"value":"0004-2803","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10,4]]}}}